AI-Driven Risk Assessment
Starting with Breast Cancer
1 in 8 Women
expected to be diagnosed with invasive breast cancer in their lifetime.50% of Women
diagnosed with breast cancer do not have an identifiable risk factor.30% of Cancers
are missed on mammography alone.60% of Women
will receive a false positive in their lifetime.Why medara?
Traditional cancer risk models rely on static data, such as a single mammogram, genetic history, or personal factors, and often focus on long-term risk projections that lack actionable solutions. medara changes that. The groundbreaking software we are developing analyzes longitudinal imaging and clinical data, to provide:
Dynamic
evaluation of a patient's imaging history and clinical risk factors.
Immediate
breast cancer risk assessment.
Actionable
comprehensive risk prediction to make informed decisions, faster.
The Power of AI Image-based Risk Prediction
Unlike tools that look at one image or rely on long-term projections, medara will assesses short-term breast cancer risk based on a patient's imaging history—offering more personalized, precise predictions.
Better Outcomes and Smarter Care for Your Patients
More Accurate, Near-term Risk Prediction
for every patient, not just those with known genetic markers or personal risk factors.
Validated, Scalable AI
developed in collaboration with leading clinicians and researchers.
Improved Operational Efficiency
through reduced unnecessary procedures and better resource management.
Patient Imaging Aquired
Following acquisition, image sets are sent to PACS.
medara™ Analysis Performed
Upon transmission to PACS, medara performs a comprehensive analysis of the patient's imaging and available clinical data to generate a personalized risk assessment.
Prioritization & Image Review
medara displays the patient-specific risk score upon radiologist review and prioritizes cases for follow-up.
